A female-led preclinical biotech start-up, Vitarka Therapeutics is focused on revolutionising the market for non-viral drug delivery technology. The company is developing combination medicines using RNAi therapies and a non-viral drug delivery platform. Their novel tumour-targeted platform technology, EndoPore, targets solid tumours and delivers therapeutics for intracellular targets.